EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate By Ogkologos - February 20, 2026 179 0 Facebook Twitter Google+ Pinterest WhatsApp New combination concerns a combination with ADT for the treatment of adult patients with mHSPC and BRCA1/2 mutations Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Recommends Additional Extensions of Indications for Pembrolizumab October 7, 2024 Can AI Help Predict Which Cancer Patients Should Be Treated with... February 26, 2025 Cancer in My Community: Caring for Children With Cancer in Paraguay June 8, 2023 Immunotherapy is Beneficial in Gastric and Oesophageal Cancers, Studies Show [ESMO2020... September 21, 2020 Load more HOT NEWS Breast Cancer Surgery Choice May Affect Young Survivors’ Quality of Life Excellence in cancer research nursing: Celebrating innovation during tough times Easing Concerns about Giving Research Study Participants Their Genetic Test Results Empoderar a las personas con cáncer: preguntas y respuestas con la...
